WireSift
← AI Adoption Tracker
WireSift Research · AI Adoption Tracker · Q1 2026

BSXBoston Scientific Corporation

AI adoption · Q1 2026 earnings call

Health CarePiloting
AI mentions
1
extracted from this call
Max specificity
2 / 5
directional only
AI revenue
Not disclosed
no breakout in this call
AI was mentioned only once on this call, briefly and in passing by CFO Jon Monson during a Q&A response about cost efficiency initiatives. He referenced 'AI automation' as one of several existing initiatives aimed at driving cost efficiency and productivity, without providing any quantification, product names, or further elaboration. AI was not a strategic focus of the call, which centered on guidance revisions related to EP, WATCHMAN, and Urology.
Public Company AI Adoption Index
Adopter
See full leaderboard →
Composite
27/ 100
#214 non-tech · #281 overall · #34 in Health Care
Depth · 40%
49
stage: piloting · max spec: 2
Disclosure · 40%
0
no quantified disclosure
Breadth · 20%
35
1 scope
Adoption scopes:internal_use
Every claim, sourced

1 AI mention from this call.

Extracted verbatim from the BSX Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.

  • T2Q&A· CFO· Internal use
    Analyst questionparaphrased· TD Cowen· Joshua Jennings
    I just wanted to touch on the EPS guidance revision. I think some may be concerned that with the deceleration in high-margin products, U.S. EP franchise and WATCHMAN franchise, there may be incremental pressure there. But any more details you can share just on any offsets or the impact on profitability with the revised outlook for U.S. EP and WATCHMAN?
    a number of AI automation, other initiatives already in place, Josh, that drive cost efficiency and productivity. And so we're looking at those for what we can accelerate.
    Jonathan Monson, BSX earnings call
Q&A Dynamics

What management wouldn’t quantify.

Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.

  1. No quantification of AI-related cost savings or productivity impact was provided despite the mention of 'AI automation' initiatives.
  2. No named AI products, platforms, or partners were disclosed.
  3. No analyst asked a follow-up question on AI, and management did not elaborate beyond a passing reference.
  4. It is unclear whether 'AI automation' refers to internal tooling, vendor solutions, or a formal program.
Stay informed

Independent research, direct to your inbox.

Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.

By subscribing, you agree to our Privacy Policy.

Sourced from primary documents · See the methodology for the extraction approach.